Health Check: Liberation Day Temporarily Shields the Global Pharmaceutical Industry

2 min read | April 01, 2025 11:00 AM AEDT | By Team Kalkine Media

Google News:

Health Check: Liberation Day Temporarily Shields the Global Pharmaceutical Industry — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Pharmaceuticals granted temporary exemption from US tariffs, with future policies under review.

ASX medical device companies adjusting manufacturing strategies to address tariff-related challenges.

Advancements in clinical trials and supply agreements shaping ASX biotech companies.

The pharmaceutical industry has received a temporary exemption from US tariffs, but discussions regarding future tariff applications persist. Pharmaceuticals exported from Europe into the US could face a baseline tariff. Australian-listed CSL (ASX:CSL) exports products derived from blood collection and continues to assess the effects of evolving US tariff policies on its operations.

Adjustments in Medical Device Manufacturing

Medical device manufacturers listed on the ASX are actively addressing the impact of tariffs on US-bound exports by evaluating local production options. Ansell (ASX:ANN), which operates manufacturing facilities in China, has been subject to a tariff, leading to a review of its pricing structure. In response, the company has announced price adjustments to offset costs. Cyclopharm (ASX:CYC) and EBR Systems (ASX:EBR) have expanded their US-based manufacturing capabilities to mitigate tariff-related issues. Compumedics (ASX:CMP) continues to monitor tariff policies to determine future manufacturing strategies. ResMed (ASX:RMD), which has lower reliance on China-based production, may experience a shift in its competitive standing within the sector.

Developments in Biotech Trials and Agreements

Orthocell (ASX:OCC) is progressing toward US regulatory approval for its nerve repair device, Remplir, following previous approvals in Australia and New Zealand. Race Oncology (ASX:RAC) has initiated a phase I trial for its drug RC-220, aimed at expanding its clinical development pipeline. Imugene (ASX:IMU) is advancing its dosage research within a US-based CD-19 biomarker trial. Bioxyne (ASX:BXN) has finalized a supply agreement, leading to an increase in revenue from a key business partner. These advancements illustrate the ongoing development across ASX-listed biotechnology companies amid broader industry adjustments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.